newsfilter
← Latest News
PR Newswire·

FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions

  • MiniMed received FDA clearance on November 16, 2026, for MiniMed Fit, its first tubeless insulin pump featuring SmartGuard™ automation.
  • The device offers up to seven days of wear without charging or cartridge changes & holds a 300-unit insulin capacity, which is 50% more than competing tubeless options.
  • MiniMed Fit combines app control on iOS & Android devices with waterproof capabilities & supports two sensor choices: Simplera Sync™ (7-day wear) & Abbott Instinct™ (15-day wear).
  • Automated insulin delivery adjusts every five minutes via SmartGuard™ technology, while Meal Detection™ assists with missed or underestimated meal doses.
  • Real-world data indicates users can achieve up to 80% Time in Range overall & 91% overnight Time in Range with recommended settings.
  • The pump is compatible with Humalog, NovoLog, & Admelog insulins & can be worn on the back of the arm, lower back, upper buttocks, abdomen, or thigh.
  • FDA clearance was achieved ahead of schedule to facilitate pharmacy channel access for U.S. customers.
  • Launch is expected to begin with a phased rollout in the U.S. in spring 2027, following an early customer experience phase in MiniMed's Q4 fiscal 2027.
  • The system is cleared for people with Type 1 & Type 2 diabetes ages 7 & older & is designed for future integration with investigational fully closed-loop technology.
Company
MiniMed
Keywords
MiniMed